Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400240 | 0.89 | ALDH1A1 (0.43) | CA2CA1ACACBNQO2ACACA | |
| SCHEMBL3128170 | 0.81 | ACACB (0.40) | CA2CA1ACACBACACAIL1B | |
| SCHEMBL1710895 | 0.81 | ACACB (0.35) | CA2CA1ACACBNQO2ACACA | |
| SCHEMBL1722782 | 0.80 | PSEN1 (0.39) | CA2CA1IL1BCA12CA9 | |
| SCHEMBL1710448 | 0.80 | CA1 (0.43) | CA2CA1NQO2CA12CA9 | |
| SCHEMBL3128178 | 0.80 | USP30 (0.39) | CA2CA1ACACBNQO2ACACA | |
| SCHEMBL3388612 | 0.79 | CA1 (0.43) | CA2CA1NQO2CA12CA9 | |
| SCHEMBL3390352 | 0.79 | CA1 (0.41) | CA2CA1ACACBNQO2CA12 | |
| SCHEMBL1727476 | 0.79 | CA1 (0.42) | CA2CA1NQO2CA12CA9 | |
| SCHEMBL1710609 | 0.77 | CA2 (0.48) | CA2CA1NQO2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | CA2 1943/4885CA1 4504/4885ACACB 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.